Literature DB >> 25545301

Comprehensive evaluation of haemostatic function in von Willebrand disease patients using a microchip-based flow chamber system.

K Ogiwara1, K Nogami, K Hosokawa, T Ohnishi, T Matsumoto, M Shima.   

Abstract

The diagnosis of von Willebrand disease (VWD) is difficult due to the wide spectrum of clinical phenotypes associated with this disorder. We have analysed and characterized haemostatic function in VWD patients using a microchip-based flow chamber system. Microchips coated with either collagen [platelet (PL)-chip] or collagen/thromboplastin [atherome (AR)-chip] were used to evaluate platelet thrombus formation at 1000 s(-1) and fibrin-rich platelet thrombus formation at 240 s(-1) respectively. Blood samples from an asymptomatic patient with VWD type 1 [von Willebrand factor (VWF): RCo 3.2%; bleeding score (BS 2] displayed normal thrombus formation in both PL- and AR-chips, whereas blood from a symptomatic type 1 patient (VWF: RCo 14%, BS 9) had significantly delayed capillary occlusion. Nearly complete suppression of the flow pressure increase was observed in symptomatic patients with VWD type 2A (BS 13) and 2N (BS 27), whereas no flow pressure was found for the type 3 patient (BS 6). Fibrin-rich platelet thrombus formation was only weakly increased by the in vitro addition of factor VIII (FVIII) to blood samples from the type 3 patient, but was normalized by the addition of VWF/FVIII. The in vivo effects of treatment with desmopressin or VWF/FVIII for the symptomatic patients were analysed using two types of microchips. The PL-chip was highly sensitive for patients' VWF-mediated platelet functions, whereas the AR-chip allowed assessment of overall haemostatic ability, including sensitivity to both VWF and FVIII. The combined analysis with PL- and AR-chips may be potentially useful for the diagnosis of VWD based on clinical phenotypes, and for monitoring drug effects.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  clinical phenotype; desmopressin; factor VIII; flow chamber system; von Willebrand disease; von Willebrand factor

Mesh:

Substances:

Year:  2015        PMID: 25545301     DOI: 10.1111/hae.12610

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  9 in total

Review 1.  Flow chamber and microfluidic approaches for measuring thrombus formation in genetic bleeding disorders.

Authors:  Rogier M Schoeman; Marcus Lehmann; Keith B Neeves
Journal:  Platelets       Date:  2017-05-22       Impact factor: 3.862

2.  Use of a microchip flow-chamber system as a screening test for platelet storage pool disease.

Authors:  Hiroaki Minami; Keiji Nogami; Kenichi Ogiwara; Shoko Furukawa; Kazuya Hosokawa; Midori Shima
Journal:  Int J Hematol       Date:  2015-06-14       Impact factor: 2.490

3.  Evaluation of clinical severity in patients with type 2N von Willebrand disease using microchip-based flow-chamber system.

Authors:  Yuto Nakajima; Keiji Nogami; Koji Yada; Takeshi Kawamura; Kenichi Ogiwara; Shoko Furukawa; Naruto Shimonishi; Masahiro Takeyama; Midori Shima
Journal:  Int J Hematol       Date:  2019-11-18       Impact factor: 2.490

4.  Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels.

Authors:  M Lehmann; K Ashworth; M Manco-Johnson; J Di Paola; K B Neeves; C J Ng
Journal:  J Thromb Haemost       Date:  2017-11-23       Impact factor: 5.824

5.  Analysis of blood clotting with the total thrombus analysis system in healthy dogs.

Authors:  Tomoko Iwanaga; Ryuji Fukushima; Tomoka Nagasato; Ikuro Maruyama; Naoki Miura
Journal:  J Vet Diagn Invest       Date:  2021-02-09       Impact factor: 1.279

6.  Evaluation of the Antithrombotic Effects of Rivaroxaban and Apixaban Using the Total Thrombus-Formation Analysis System®: In Vitro and Ex Vivo Studies.

Authors:  Hidekazu Sugihara; Yoshiaki Idemoto; Takashi Kuwano; Yoshihisa Nagata; Joji Morii; Makoto Sugihara; Masahiro Ogawa; Shin-Ichiro Miura; Keijiro Saku
Journal:  J Clin Med Res       Date:  2016-10-26

7.  Detection of acquired von Willebrand syndrome after ventricular assist device by total thrombus-formation analysis system.

Authors:  Seiji Takashio; Koichi Kaikita; Masato Nishi; Mami Morioka; Taiki Higo; Akira Shiose; Tsuyoshi Doman; Hisanori Horiuchi; Toshihiro Fukui; Kenichi Tsujita
Journal:  ESC Heart Fail       Date:  2020-07-23

8.  Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial.

Authors:  Kenichi Ogiwara; Masashi Taki; Takashi Suzuki; Hideyuki Takedani; Tadashi Matsushita; Kagehiro Amano; Masanori Matsumoto; Kenji Nishio; Midori Shima; Masato Kasahara; Keiji Nogami
Journal:  BMJ Open       Date:  2022-02-17       Impact factor: 2.692

9.  Platelet thrombus formation in patients with end-stage renal disease before and after hemodialysis as measured by the total thrombus-formation analysis system.

Authors:  Branka P Mitic; Zorica M Dimitrijevic; Kazuya Hosokawa; Tatjana P Cvetkovic; Milan V Lazarevic; Danijela D Tasic; Andriana Jovanovic; Nina Jancic; Tamara Vrecic; Anna Ågren; Håkan Wallen
Journal:  Int Urol Nephrol       Date:  2022-04-02       Impact factor: 2.266

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.